Therapeutic HSV-2 Vaccine Candidate Rights Transferred

Sweden-based Eurocine Vaccines AB announced today that the company has entered into a research and collaboration agreement with Redbiotec AG that transfers the exclusive global rights to develop, manufacture, and commercialize vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2) based on the technologies developed by Redbiotec.

The agreement covers both an mRNA and a protein-based technology and patents within the field of HSV-2.

"I am very pleased that we have added this promising (vaccine) candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec," says CEO Hans Arwidsson, Eurocine Vaccines, in a press release issued on June 14, 2022.

This program is essential since the U.S. FDA has not authorized an HSV-2 vaccine.

HSV-2 is a sexually transmitted disease that affects about half a billion people worldwide, according to the WHO.

Implications that follow include painful genital blisters and/or ulcers, depression resulting from the negative impact on quality of life and sexual relationships, increased risk of HIV, neurological disabilities due to neonatal herpes, and in rare cases, encephalitis.

"We are very content to have engaged Eurocine Vaccines for the leap ahead, taking our novel HSV-2 candidates from innovation towards a potential blockbuster."

"Eurocine Vaccines has proven to be one of the few vaccine experts who are engaged, committed, and able to do just that," added Christian Schaub, co-founder, and CEO of Redbiotec.

Read more about the development process and how the company bridges the gap between innovation and the market: https://www.eurocine-vaccines.com/bridging-the-gap/.

Additional HSV vaccine candidates are listed at PrecisionVaccinations.com/Herpes.

Note: This announcement was manually curated for mobile readership.